{
    "ticker": "OMER",
    "name": "Omeros Corporation",
    "description": "Omeros Corporation is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for a range of medical conditions. Founded in 1994 and headquartered in Seattle, Washington, Omeros is committed to addressing unmet medical needs through its proprietary discovery platform and product pipeline. The company's lead product, Omidria, is an intraoperative analgesic that is used during cataract surgery to alleviate pain and maintain pupil dilation. In addition to Omidria, Omeros has a robust pipeline of product candidates targeting indications in the fields of ophthalmology, hematology, and immunology. The company's approach integrates rigorous scientific research with a patient-centered philosophy, striving to improve the quality of life for patients suffering from serious conditions. Omeros's commitment to innovation is evident in its ongoing efforts to develop new therapies that can provide meaningful benefits to patients and healthcare providers alike. With a focus on clinical excellence and regulatory compliance, Omeros is dedicated to advancing its product candidates through rigorous clinical trials and obtaining necessary regulatory approvals to bring new treatments to market.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Seattle, Washington, USA",
    "founded": "1994",
    "website": "https://www.omeros.com",
    "ceo": "Gregory A. Demopulos",
    "social_media": {
        "twitter": "https://twitter.com/OmerosCorp",
        "linkedin": "https://www.linkedin.com/company/omeros-corporation/"
    },
    "investor_relations": "https://www.omeros.com/investors/",
    "key_executives": [
        {
            "name": "Gregory A. Demopulos",
            "position": "CEO"
        },
        {
            "name": "Michael A. P. D. B. H. C. C. H. B. C. C. K. C.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Products",
            "products": [
                "Omidria"
            ]
        },
        {
            "category": "Pipeline Products",
            "products": [
                "OMS721",
                "OMS527"
            ]
        }
    ],
    "seo": {
        "meta_title": "Omeros Corporation | Innovative Biopharmaceuticals",
        "meta_description": "Explore Omeros Corporation, a biopharmaceutical company dedicated to developing innovative therapeutics for unmet medical needs. Learn about our products and pipeline.",
        "keywords": [
            "Omeros",
            "Biopharmaceuticals",
            "Omidria",
            "Innovative Therapies",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Omeros known for?",
            "answer": "Omeros is known for its biopharmaceutical innovations, particularly its lead product Omidria for cataract surgery."
        },
        {
            "question": "Who is the CEO of Omeros?",
            "answer": "Gregory A. Demopulos is the CEO of Omeros Corporation."
        },
        {
            "question": "Where is Omeros headquartered?",
            "answer": "Omeros is headquartered in Seattle, Washington, USA."
        },
        {
            "question": "What are Omeros's main products?",
            "answer": "Omeros's main products include Omidria, with additional candidates in the pipeline like OMS721 and OMS527."
        },
        {
            "question": "When was Omeros founded?",
            "answer": "Omeros was founded in 1994."
        }
    ],
    "competitors": [
        "VRTX",
        "AMGN",
        "REGN",
        "VRTX"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "JNJ",
        "PFE"
    ]
}